General Information
Drug ID
DR00066
Drug Name
Cidofovir
Synonyms
(2S)-3-Hydroxy-2-phosphonylmethoxypropyl-cytosine; (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine; (S)-1-[3-hydroxy-2-(phosphonylmethoxy)-propyl]cytosine; (S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl-1-(hydroxymethyl)ethoxy)methyl phosphonic acid; (S)-HPMPC; (s)-[[2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid; ({[(2S)-1-(4-amino-2-oxopyrimidin-1(2H)-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid; 1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine; 1-[(S)-3-Hydroxy-2-(phosphonomethoxy)propyl]-cytosine dihydrate; CDV; Cidofovir (Vistide); Cidofovir (anhydrous); Cidofovir anhydrous; Cidofovirum; Forvade; GS 0504; GS 504; GS-0504; GS-504; GS504; HPMPC; Vistide; Vistide (TN); Vistide, Cidofovir; [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
Drug Type
Small molecular drug
Indication Cytomegalovirus infections [ICD11: 1D82] Approved [1]
Therapeutic Class
Anti-HIV Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=60613"></iframe>
3D MOL 2D MOL
Formula
C8H14N3O6P
Canonical SMILES
C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O
InChI
InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1
InChIKey
VWFCHDSQECPREK-LURJTMIESA-N
CAS Number
CAS 113852-37-2
Pharmaceutical Properties Molecular Weight 279.189 Topological Polar Surface Area 146
Heavy Atom Count 18 Rotatable Bond Count 6
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 6
PubChem CID
60613
PubChem SID
103208535 , 104253188 , 104321212 , 109692921 , 117588193 , 12014233 , 124757308 , 124896571 , 125164112 , 126628422 , 126655266 , 126664430 , 126669928 , 129535965 , 134222323 , 134338340 , 135018697 , 136920390 , 136946528 , 136949097 , 137005936 , 142388054 , 144115830 , 144206546 , 14848679 , 14972788 , 151994247 , 160963716 , 162011514 , 164778525 , 164807829 , 174007460 , 175268249 , 179149625 , 196106556 , 196403991 , 210275592 , 210281251 , 43117987 , 46506054 , 50007425 , 57314045 , 596838 , 76063703 , 7978941 , 8186963 , 85240541 , 91146456 , 92718864 , 93578310
ChEBI ID
CHEBI:3696
TTD Drug ID
D04AAW
DT(s) Transporting This Drug MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
OAT1 Transporter Info Organic anion transporter 1 Substrate [3]
OAT3 Transporter Info Organic anion transporter 3 Substrate [3]
Drug-Transporter Activity Data
Drug-Transporter Activity Data OAT1 Transporter Info Km = 30 microM Chinese hamster ovary (CHO) cells-OAT1 [4]
OAT1 Transporter Info Km = 58 microM Chinese hamster ovary (CHO) cells-OAT1 [5]
OAT1 Transporter Info Km = 46 microM Oocytes-OAT1 [6]
References
1 Cidofovir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
3 Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007 Apr;24(4):811-5.
4 Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007 May;321(2):673-83.
5 Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J Am Soc Nephrol. 2000 Mar;11(3):383-93.
6 The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1. Mol Pharmacol. 1999 Sep;56(3):570-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.